Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein

Journal of Virology

Volumn 85, Issue 11, 2011, Pages 5546-5554

  Genovese, Nicholas J ^a   Broker, Thomas R ^a   Chow, Louise T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; LYSINE; PROTEASOME; PROTEIN E7; PROTEIN P130; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA REPLICATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; VIRUS CELL INTERACTION; VIRUS ENTRY; WART VIRUS;

AMINO ACID SUBSTITUTION; CRK-ASSOCIATED SUBSTRATE PROTEIN; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; LYSINE; MUTANT PROTEINS; PAPILLOMAVIRUS E7 PROTEINS; PROTEIN INTERACTION MAPPING; S PHASE; VIRULENCE FACTORS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 79956067301     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02166-10     Document Type: Article

References (67)

1. Armstrong, D. J., and A. Roman. 1995. Human papillomavirus type 6 E7 protein is a substrate in vitro of protein kinase C. Biochem. J. 312:667-670.
2. Balsitis, S. J., et al. 2003. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol. Cell. Biol. 23:9094-9103.
3. Banerjee, N. S., et al. 2006. Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes. J. Virol. 80:6517-6524. 3a.
4. Banerjee, N. S., H.-K. Wang, T. R. Broker, and L. T. Chow. 2011. Human papillomavirus (HPV) E7 induces prolonged G2 following S-phase recentry in differentiated human keratinocytes. J. Biol. Chem. 286:15473-15482.
5. Ben-Saadon, R., et al. 2004. The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysineless proteins that are degraded by the ubiquitin system-direct evidence for ubiquitination at the N-terminal residue. J. Biol. Chem. 279:41414-41421.
6. Berezutskaya, E., B. Yu, A. Morozov, P. Raychaudhuri, and S. Bagchi. 1997. Differential regulation of the pocket domains of the retinoblastoma family proteins by the HPV16 E7 oncoprotein. Cell Growth Differ. 8:1277-1286.
7. Boyer, S. N., D. E. Wazer, and V. Band. 1996. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:4620-4624.
8. Caldeira, S., E.-M. de Villiers, and M. Tommasino. 2000. Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein. Oncogene 19:821-826.
9. Callis, J., and R. Ling. 2005. Preparation, characterization, and use of tagged ubiquitins. Methods Enzymol. 399:51-64.
10. Chellappan, S., et al. 1992. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc. Natl. Acad. Sci. U. S. A. 89:4549-4553.
11. Chemes, L. B., I. E. Sánchez, C. Smal, and G. De Prat-Gay. 2010. Targeting mechanism of the retinoblastoma tumor suppressor by a prototypical viral oncoprotein. FEBS J. 277:973-988.
12. Cheng, S., D.-C. Schmidt-Grimminger, T. Murant, T. R. Broker, and L. T. Chow. 1995. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9:2335-2349.
13. Chien, W.-M., F. Noya, H. M. Benedict-Hamilton, T. R. Broker, and L. T. Chow. 2002. Alternative fates of keratinocytes transduced by human papillomavirus type 18 E7 during squamous differentiation. J. Virol. 76:2964-2972.
14. Chien, W.-M., J. N. Parker, D.-C. Schmidt-Grimminger, T. R. Broker, and L. T. Chow. 2000. Casein kinase II phosphorylation of the human papillomavirus-18 E7 protein is critical for promoting S-phase entry. Cell Growth Differ. 11:425-435.
15. Ciccolini, F., G. Dipasquale, F. Carlotti, L. Crawford, and M. Tommasino. 1994. Functional studies of E7 proteins from different HPV types. Oncogene 9:2633-2638.
16. Darnell, G. A., et al. 2007. Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. J. Biol. Chem. 282:37492-37500.
17. de Villiers, E.-M., C. Fauquet, T. R. Broker, H.-U. Bernard, and H. zur Hausen. 2004. Classification of papillomaviruses. Virology 324:17-27.
18. Gammoh, N., et al. 2009. Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2. Oncogene 28:2299-2304.
19. García-Alai, M. M., L. G. Alonso, and G. de Prat-Gay. 2007. The N-terminal module of HPV16 E7 is an intrinsically disordered domain that confers conformational and recognition plasticity to the oncoprotein. Biochemistry 46:10405-10412.
20. Genovese, N. J., N. S. Banerjee, T. R. Broker, and L. T. Chow. 2008. Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J. Virol. 82:4862-4873.
21. Giarre', M., et al. 2001. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16(INK4a)-imposed G(1) cell cycle arrest. J. Virol. 75:4705-4712.
22. Goldschmidt, L., D. R. Cooper, Z. S. Derewenda, and D. Eisenberg. 2007. Toward rational protein crystallization: a web server for the design of crystallizable protein variants. Protein Sci. 16:1569-1576.
23. Gonzalez, S. L., M. Stremlau, X. He, J. R. Basile, and K. Münger. 2001. Degradation of the retinoblastoma tumor suppressor by the human papillo-mavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 75:7583-7591.
24. Halbert, C. L., G. W. Demers, and D. A. Galloway. 1992. The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66:2125-2134.
25. Heck, D. V., C. L. Yee, P. M. Howley, and K. Münger. 1992. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. U. S. A. 89:4442-4446.
26. Helt, A.-M., and D. A. Galloway. 2001. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J. Virol. 75:6737-6747.
27. Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425-479.
28. Huang, P. S., et al. 1993. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol. Cell. Biol. 13:953-960.
29. Huh, K., et al. 2007. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81:9737-9747.
30. Kaiser, P., and C. Tagwerker. 2005. Is this protein ubiquitinated? Methods Enzymol. 399:243-248.
31. Knapp, A. A., P. M. McManus, K. Bockstall, and J. Moroianu. 2009. Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein. Virology 383:60-68.
32. Liang, Y.-J., H.-S. Chang, C.-Y. Wang, and W. C. Y. Yu. 2008. DYRK1A stabilizes HPV16E7 oncoprotein through phosphorylation of the threonine 5 and threonine 7 residues. Int. J. Biochem. Cell Biol. 40:2431-2441.
33. Lipford, J. R., and R. J. Deshaies. 2003. Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. Nat. Cell Biol. 5:845-850.
34. Liu, X., A. Clements, K. Zhao, and R. Marmorstein. 2006. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 281:578-586.
35. Lo Conte, L., C. Chothia, and J. Janin. 1999. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285:2177-2198.
36. Mani, A., and E. P. Gelmann. 2005. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 23:4776-4789.
37. Markowitz, D., S. Goff, and A. Bank. 1988. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400-406.
38. McLaughlin-Drubin, M. E., and K. Münger. 2009. The human papillomavirus E7 oncoprotein. Virology 384:335-344.
39. Moody, C. A., and L. A. Laimins. 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10:550-560.
40. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
41. Oh, K.-J., A. Kalinina, and S. Bagchi. 2010. Destabilization of Rb by human papillomavirus E7 is cell cycle dependent: E2-25K is involved in the proteolysis. Virology 396:118-124.
42. Oh, K.-J., et al. 2004. The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1-and Skp2-containing E3 ligase. J. Virol. 78:5338-5346.
43. Oh, S. T., M. S. Longworth, and L. A. Laimins. 2004. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J. Virol. 78:2620-2626.
44. Paramio, J. M., S. Lain, C. Segrelles, E. B. Lane, and J. L. Jorcano. 1998. Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation. Oncogene 17:949-957.
45. Patel, D., and D. J. McCance. 2010. Compromised spindle assembly checkpoint due to altered expression of ubch10 and cdc20 in human papillomavirus type 16 E6-and E7-expressing keratinocytes. J. Virol. 84:10956-10964.
46. Piccioli, Z., et al. 2010. The nuclear localization of low risk HPV11 E7 protein mediated by its zinc binding domain is independent of nuclear import receptors. Virology 407:100-109.
47. Reinstein, E., M. Scheffner, M. Oren, A. Ciechanover, and A. Schwartz. 2000. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitinproteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19:5944-5950.
48. Ruiz, S., et al. 2004. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 131:2737-2748.
49. Salghetti, S. E., M. Muratani, H. Wijnen, B. Futcher, and W. P. Tansey. 2000. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc. Natl. Acad. Sci. U. S. A. 97:3118-3123.
50. Sang, B. C., and M. S. Barbosa. 1992. Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc. Natl. Acad. Sci. U. S. A. 89:8063-8067.
51. Schmitt, A., J. B. Harry, B. Rapp, F. O. Wettstein, and T. Iftner. 1994. Comparison of the properties of the E6 and E7 genes of low-and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. J. Virol. 68:7051-7059.
52. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.
53. Smith-McCune, K., et al. 1999. Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130. Proc. Natl. Acad. Sci. U. S. A. 96:6999-7004.
54. Smotkin, D., and F. O. Wettstein. 1987. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 61: 1686-1689.
55. Sun, A., L. Bagella, S. Tutton, G. Romano, and A. Giordano. 2007. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J. Cell. Biochem. 102:1400-1404.
56. Thomas, J. T., W. G. Hubert, M. N. Ruesch, and L. A. Laimins. 1999. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc. Natl. Acad. Sci. U. S. A. 96:8449-8454.
57. Ueno, T., et al. 2006. Molecular mechanisms of hyperplasia induction by human papillomavirus E7. Oncogene 25:4155-4164.
58. Uversky, V. N., A. Roman, C. J. Oldfield, and A. K. Dunker. 2006. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs. J. Proteome Res. 5:1829-1842.
59. Wang, B., K. Liu, F.-T. Lin, and W.-C. Lin. 2004. A role for 14-3-3τ in E2F1 stabilization and DNA damage-induced apoptosis. J. Biol. Chem. 279:54140-54152.
60. Wang, H.-K., A. A. Duffy, T. R. Broker, and L. T. Chow. 2009. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev. 23:181-194.
61. Wang, J., A. Sampath, P. Raychaudhuri, and S. Bagchi. 2001. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 20:4740-4749.
62. Ward, C. L., S. Omura, and R. R. Kopito. 1995. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83:121-127.
63. Wilson, J. L., S. C. Dollard, L. T. Chow, and T. R. Broker. 1992. Epithelialspecific gene expression during differentiation of stratified primary human keratinocyte cultures. Cell Growth Differ. 3:471-483.
64. Xiao, B., et al. 2003. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc. Natl. Acad. Sci. U. S. A. 100:2363-2368.
65. Yan, C., F. Wu, R. L. Jernigan, D. Dobbs, and V. Honavar. 2008. Characterization of protein-protein interfaces. Protein J. 27:59-70.
66. Zhang, B., W. Chen, and A. Roman. 2006. The E7 proteins of low-and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc. Natl. Acad. Sci. U. S. A. 103:437-442.
67. zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2:342-350.